- During the placebo-controlled phase, significantly greater reductions in TJC and SJC were achieved with OTEZLA 30 mg BID vs placebo at week 16 (TJC: -42.9% vs -7%, respectively; SJC: -50% vs -16.7%, respectively; P < 0.0001 for both)2*
This site is intended for healthcare professionals outside the U.S.
PALACE 1 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.
PALACE 1-3 pooled analysis. Per-protocol population, LOCF.
BL, baseline; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; SJC, swollen joint count; TJC, tender joint count.
References: 1. Kavanaugh A, Gladman DD, Gomez-Reino JJ, et al. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 2016. 2. Cutolo M, Mease PJ, Gladman D, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials. Presented at: the 2013 ACR/ARHP Annual Meeting; October 26–30, 2013; San Diego, CA. Abstract 317.
Please choose a country